Tyrosine Kinase 2 Inhibition with Zasocitinib (Tak-279) in Psoriasis

This randomized clinical trial found that potent and selective inhibition of tyrosine kinase 2 with zasocitinib at oral doses of five mg or more once daily resulted in greater skin clearance than placebo over 12 weeks.